R

Radiopharm Theranostics Ltd
NASDAQ:RADX

Watchlist Manager
Radiopharm Theranostics Ltd
NASDAQ:RADX
Watchlist
Price: 4.655 USD 0.32% Market Closed
Market Cap: 10.9B USD

EV/EBIT
Enterprise Value to EBIT

-0.3
Current
-0.6
Median
4.5
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-0.3
=
Enterprise Value
12m AUD
/
EBIT
-37.8m AUD
EBIT Growth EV/EBIT to Growth
AU
R
Radiopharm Theranostics Ltd
NASDAQ:RADX
Average EV/EBIT: 19.6
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 495.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.4
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.6
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.8 N/A N/A
AU
CSL Ltd
ASX:CSL
21
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -345.5 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-0.2
2-Years Forward
EV/EBIT
-0.3
3-Years Forward
EV/EBIT
-0.2